Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Kisqali Femara Co-Pack

(kis-KAH-lee feh-MUH-ruh KOH-pak)
A combination pack of two drugs used to treat adults with certain types of hormone-receptor positive, HER2-negative breast cancer. It is also being studied in the treatment of other types of cancer. Ribociclib succinate blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Letrozole lowers the amount of estrogen made by the body, which may stop the growth of cancer cells that need estrogen to grow. It is a type of aromatase inhibitor. Kisqali Femara Co-Pack may work better than either drug alone. Also called ribociclib succinate and letrozole.
More Information
Search NCI's Dictionary of Cancer Terms